A multi-center, randomized, double-blinded, placebo-controlled trial of additive effect of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: JORTC- PAL08 (DIRECT study).

Eriko Satomi,Hiromichi Matsuoka,Satoru Iwase,Tempei Miyaji,Takashi Kawaguchi,Keisuke Ariyoshi,Shunsuke Oyamada,Hideaki Hasuo,Akihiro Tokoro,Toshiaki Shinomiya,Hiroaki Tsukuura,Yoichi Otake,Masatomo Otsuka,Yoshikazu Hasegawa,Yoshihisa Matsumoto,Yuki Kataoka,Hiroyuki Otani,Yasuhiro Kidera, Mayuri Aoyama,Takuhiro Yamaguchi

Journal of Clinical Oncology（2018）

引用 1|浏览20

暂无评分

摘要

10102Background: Management of cancer patients experiencing neuropathic pain (NP) refractory to opioids remains an important challenge. Gabapentinoids are one of the most widely used therapies for ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要